Oregon Psilocybin Services to host First Public Hearings on Proposed rules Tomorrow
Salem, OR - Oregonians will have their first opportunity to publicly weigh in on the rules governing the state’s groundbreaking psilocybin services program beginning tomorrow night, as the Oregon Psilocybin Services (OPS) launches a series of public hearings. The hearings represent a critical step in finalizing the framework for legal access to psilocybin-assisted therapy, a program approved by voters in 2020.
Thes hearings are designed to gather feedback on proposed administrative rules that will dictate how psilocybin services are licensed, operated, and accessed across the state. the rules cover a wide range of topics, including facilitator training, manufacturing standards, and client safety protocols. the outcome of these hearings will directly impact the implementation of Measure 109, shaping the future of psilocybin access for Oregonians and perhaps serving as a model for other states considering similar legislation.
The first hearing is scheduled for tomorrow, July 11th, from 6:00 PM to 9:00 PM PST. Participants can join via Zoom at [Zoom Meeting Link]. OPS officials state that all participants will have an opportunity to share comments, nonetheless of advance sign-up.
OPS is committed to accessibility, offering Spanish interpretation, American Sign Language interpretation, and live transcript/CART captioning services during the hearings. Individuals needing accommodations or assistance can contact the OPS team at 971-341-1713, 711 TTY, or via email at OHA.Psilocybin@odhsoha.oregon.gov. Requests received at least 48 hours in advance are preferred, though early submissions are encouraged.
Further information regarding the public comment period and proposed rules is available on the OPS Administrative Rules page: https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Administrative-Rules.aspx?utm_medium=email&utm_source=govdelivery. More details about Oregon Psilocybin Services can be found at www.oregon.gov/psilocybin.